@article {35402,
	title = {Synergistic enzymatic and bioorthogonal reactions for selective prodrug activation in living systems},
	journal = {Nature CommunicationsNature Communications},
	volume = {9},
	number = {1},
	year = {2018},
	note = {TZ-Peptide, TCO-Dox, mice},
	month = {2018/11/28},
	pages = {5032},
	abstract = {Adverse drug reactions (ADRs) restrict the maximum doses applicable in chemotherapy, which leads to failure in cancer treatment. Various approaches, including nano-drug and prodrug strategies aimed at reducing ADRs, have been developed, but these strategies have their own pitfalls. A renovated strategy for ADR reduction is urgently needed. Here, we employ an enzymatic supramolecular self-assembly process to accumulate a bioorthogonal decaging reaction trigger inside targeted cancer cells, enabling spatiotemporally controlled, synergistic prodrug activation. The bioorthogonally activated prodrug exhibits significantly enhanced potency against cancer cells compared with normal cells. This prodrug activation strategy further demonstrates high tumour inhibition efficacy with satisfactory biocompatibility, pharmacokinetics, and safety in vivo. We envision that integration of enzymatic and bioorthogonal reactions will serve as a general small-molecule-based strategy for alleviation of ADRs in chemotherapy.},
	isbn = {2041-1723},
	author = {Yao, Qingxin and Feng Lin and Xinyuan Fan and Wang, Yanpu and Liu, Ye and Liu, Zhaofei and Jiang, Xingyu and Peng R. Chen and Gao, Yuan}
}
